Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. Revolution Medicines Inc. is based in CA, United States.
| Revenue (Most Recent Fiscal Year) | $11.58M |
| Net Income (Most Recent Fiscal Year) | $-600.09M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.44 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -41.78% |
| Return on Assets (Trailing 12 Months) | -35.63% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.79 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.79 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.13 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $13.47 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.31 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.58 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.50 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 186.93M |
| Free Float | 171.60M |
| Market Capitalization | $10.18B |
| Average Volume (Last 20 Days) | 2.15M |
| Beta (Past 60 Months) | 1.27 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 94.34% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |